Company intelligence / Profile preview
TScan Therapeutics, Inc.
Waltham, Massachusetts, United Statestscan.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TScan Therapeutics develops engineered T cell receptor therapies targeting both hematologic malignancies and solid tumors. Its lead candidates—TSC‑100 and TSC‑101—are in Phase I trials for AML, MDS, and ALL in the context of allogeneic HCT. The company also has additional preclinical programs focused on expanding its pipeline to other cancers. No pivotal efficacy data have been reported yet; the focus remains on early safety/tolerability and proof-of-concept studies.
- Therapeutic areas
- OncologyHematology
- Modalities
- T cell receptor-engineered T cells (TCR-T)Cell therapy
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Beyond the preview
Go deeper on TScan Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TScan Therapeutics, Inc..